Page last updated: 2024-08-23

dobutamine and istaroxime

dobutamine has been researched along with istaroxime in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adamson, PB; Carminati, P; Gagnol, JP; Germany, R; Mattera, GG; Schwartz, PJ; Vanoli, E1
Borsini, F; Carminati, P; Gagnol, JP; Loi, FM; Mattera, GG; Vanoli, E1
Blair, JE; Filippatos, GS; Gheorghiade, M; Harinstein, ME; Khan, H; Metra, M; Porchet, H; Sabbah, HN; Valentini, G; Vogel, M1
Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; ZacĂ , V1
Campia, U; Gheorghiade, M; Nodari, S1

Reviews

2 review(s) available for dobutamine and istaroxime

ArticleYear
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
    Heart failure reviews, 2009, Volume: 14, Issue:4

    Topics: Acute Disease; Animals; Cardiotonic Agents; Dobutamine; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Pulmonary Wedge Pressure; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Potassium-Exchanging ATPase

2009
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
    Heart failure reviews, 2009, Volume: 14, Issue:4

    Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents

2009

Other Studies

3 other study(ies) available for dobutamine and istaroxime

ArticleYear
Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure.
    Journal of cardiovascular pharmacology, 2003, Volume: 42, Issue:2

    Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Etiocholanolone; Heart Failure; Hemodynamics; Ventricular Dysfunction, Left

2003
Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent.
    European journal of heart failure, 2008, Volume: 10, Issue:10

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Dobutamine; Dogs; Etiocholanolone; Male; Milrinone; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Sodium-Potassium-Exchanging ATPase; Sympathomimetics; Time Factors; Treatment Failure; Ventricular Dysfunction, Left

2008
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
    Current heart failure reports, 2010, Volume: 7, Issue:3

    Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobutamine; Etiocholanolone; Genetic Therapy; Heart Failure; Humans; Hydrazones; Pyridazines; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Potassium-Exchanging ATPase; Urea

2010